doi:10.48130/git-0025-0001

[1]

Siegel RL, Miller KD, Fuchs HE, Jemal A. 2022. Cancer statistics, 2022. CA: A Cancer Journal for Clinicians 72:7−33

doi: 10.3322/caac.21708

[2]

Zhang Y, Liu X, Wang Y, Lai S, Wang Z, et al. 2022. The m⁶A demethylase ALKBH5-mediated upregulation of DDIT4-AS1 maintains pancreatic cancer stemness and suppresses chemosensitivity by activating the mTOR pathway. Molecular Cancer 21:174

doi: 10.1186/s12943-022-01647-0

[3]

Ansari D, Tingstedt B, Andersson B, Holmquist F, Sturesson C, et al. 2016. Pancreatic cancer: yesterday, today and tomorrow. Future Oncology 12:1929−46

doi: 10.2217/fon-2016-0010

[4]

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, et al. 2016. Cancer statistics in China, 2015. CA: A Cancer Journal for Clinicians 66:115−32

doi: 10.3322/caac.21338

[5]

Stolzenberg-Solomon RZ, Schairer C, Moore S, Hollenbeck A, Silverman DT. 2013. Lifetime adiposity and risk of pancreatic cancer in the NIH-AARP diet and health study cohort. American Journal of Clinical Nutrition 98:1057−65

doi: 10.3945/ajcn.113.058123

[6]

Blackford A, Parmigiani G, Kensler TW, Wolfgang C, Jones S, et al. 2009. Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Research 69:3681−88

doi: 10.1158/0008-5472.CAN-09-0015

[7]

Spanknebel K, Conlon KC. 2001. Advances in the surgical management of pancreatic cancer. Cancer Journal 7:312−23

[8]

Park W, Chawla A, O'Reilly EM. 2021. Pancreatic cancer: a review. JAMA 326:851−62

doi: 10.1001/jama.2021.13027

[9]

Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, et al. 2013. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New England Journal of Medicine 369:1691−703

doi: 10.1056/NEJMoa1304369

[10]

Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, et al. 2018. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. The New England Journal of Medicine 379:2395−406

doi: 10.1056/NEJMoa1809775

[11]

Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, et al. 2014. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. The Lancet Oncology 15:1224−35

doi: 10.1016/S1470-2045(14)70420-6

[12]

Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, et al. 2014. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384:665−73

doi: 10.1016/S0140-6736(14)60845-X

[13]

Liu ZL, Chen HH, Zheng LL, Sun LP, Shi L. 2023. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduction and Targeted Therapy 8:198

doi: 10.1038/s41392-023-01460-1

[14]

Hoff PM, Machado KK. 2012. Role of angiogenesis in the pathogenesis of cancer. Cancer Treatment Reviews 38:825−33

doi: 10.1016/j.ctrv.2012.04.006

[15]

Shen G, Zheng F, Ren D, Du F, Dong Q, et al. 2018. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. Journal of Hematology & Oncology 11:120

doi: 10.1186/s13045-018-0664-7

[16]

Li S, Niu M, Deng W, Li N, Wei C, Luo S. 2022. Anlotinib is effective in the treatment of advanced pancreatic cancer: a case report. Anti-Cancer Drugs 33:e558−e561

doi: 10.1097/CAD.0000000000001173

[17]

Luo D, Liao S, Li Q, Lin Y, Wei J, et al. 2022. Case report: A case of locally advanced pancreatic cancer which achieved progression free for over 12 months by subsequent therapy with anlotinib hydrochloride plus Tegafur-Gimeracil-Oteracil Potassium (TS-1). Frontiers in Oncology 12:862600

doi: 10.3389/fonc.2022.862600

[18]

Wang Y, Wang B, Xiang L, Deng J, Xu B, et al. 2022. Case Report: Anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX Chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: a case and literature review. Frontiers in Immunology 13:1016647

doi: 10.3389/fimmu.2022.1016647

[19]

Han B, Li K, Zhao Y, Li B, Cheng Y, et al. 2018. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). British Journal of Cancer 118:654−61

doi: 10.1038/bjc.2017.478

[20]

Xu Q, Wang J, Sun Y, Lin Y, Liu J, et al. 2022. Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: a multicenter, single-arm, prospective phase II trial. ournal of Clinical Oncology 40:1795−805

doi: 10.1200/JCO.21.02091

[21]

Sun Y, Zhou A, Zhang W, Jiang Z, Chen B, et al. 2021. Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study). Hepatol Int 15:621−29

doi: 10.1007/s12072-021-10171-0

[22]

Zhou AP, Bai Y, Song Y, Luo H, Ren XB, et al. 2019. Anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma: a randomized phase II clinical trial. The Oncologist 24:e702−e08

doi: 10.1634/theoncologist.2018-0839

[23]

Ma J, Song Y, Shou J, Bai Y, Li H, et al. 2020. Anlotinib for patients with metastatic renal cell carcinoma previously treated with one vascular endothelial growth factor receptor-tyrosine kinase inhibitor: a phase 2 trial. Frontiers in Oncology 10:664

doi: 10.3389/fonc.2020.00664

[24]

Huang J, Xiao J, Fang W, Lu P, Fan Q, et al. 2021. Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: a double-blind randomized phase 2 trial. Investigational New Drugs 10:1681−89

doi: 10.1002/cam4.3771

[25]

Li J, Liang H, He J, Sui X, Qin Y. 2021. Anlotinib combined with chemotherapy for recurrence of pulmonary sarcomatoid cancer previously surgically treated: a case report and literature review. Frontiers in Oncology 11:639168

doi: 10.3389/fonc.2021.639168

[26]

Liu S, Zhi W, Zhang L. 2024. Efficacy of anlotinib in Chinese patients with metastatic breast cancer: a retrospective observational study. Journal of Cellular and Molecular Medicine 28:e18008

doi: 10.1111/jcmm.18008

[27]

Teraoka H, Sawada T, Nishihara T, Yashiro M, Ohira M, et al. 2001. Enhanced VEGF production and decreased immunogenicity induced by TGF-β1 promote liver metastasis of pancreatic cancer. British Journal of Cancer 85:612−17

doi: 10.1054/bjoc.2001.1941

[28]

Zhan G, Hu J, Da S, Weng J, Zhou C, et al. 2023. A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer. Frontiers in Endocrinology 14:1110624

doi: 10.3389/fendo.2023.1110624

[29]

Sha H, Tong F, Ni J, Sun Y, Zhu Y, et al. 2024. First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial. Signal Transduction and Targeted Therapy 9:143

doi: 10.1038/s41392-024-01857-6

[30]

Bhargavan R, Philip FA, Km JK, Augustine P, Thomas S. 2024. Comparison of modified frailty index, clinical frailty scale, ECOG score, and ASA PS score in predicting postoperative outcomes in cancer surgery: a prospective study. Indian Journal of Surgical Oncology 15(4):938−45

doi: 10.1007/s13193-024-01995-x

[31]

Li S, Wang H. 2023. Research progress on mechanism and management of adverse drug reactions of anlotinib. Drug Design, Development and Therapy 17:3429−37

doi: 10.2147/DDDT.S426898

[32]

Burris HA, 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, et al. 1997. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of Clinical Oncology 15:2403−13

doi: 10.1200/JCO.1997.15.6.2403

[33]

National Health Commission Of The People's Republic Of China. 2019. Chinese guidelines for diagnosis and treatment of pancreatic cancer 2018 (English version). Chinese Journal of Cancer Research 31:278−94

doi: 10.21147/j.issn.1000-9604.2019.02.03

[34]

Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, et al. 2021. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 19:439−57

doi: 10.6004/jnccn.2021.0017

[35]

Dallas NA, Gray MJ, Xia L, Fan F, van Buren G, 2nd, et al. 2008. Neuropilin-2-mediated tumor growth and angiogenesis in pancreatic adenocarcinoma. Clinical Cancer Research 14:8052−60

doi: 10.1158/1078-0432.CCR-08-1520

[36]

Pang N, Yang Z, Zhang W, Du Y, Zhang L, et al. 2024. Cancer-associated fibroblasts barrier breaking via TGF-β blockade paved way for docetaxel micelles delivery to treat pancreatic cancer. International Journal of Pharmaceutics 665:124706

doi: 10.1016/j.ijpharm.2024.124706

[37]

Lee J, Lee J, Yun JH, Choi C, Cho S, et al. 2017. Autocrine DUSP28 signaling mediates pancreatic cancer malignancy via regulation of PDGF-A. Scientific Reports 7:12760

doi: 10.1038/s41598-017-13023-w

[38]

Kindler HL, Wroblewski K, Wallace JA, Hall MJ, Locker G, et al. 2012. Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Investigational New Drugs 30:382−6

doi: 10.1007/s10637-010-9526-z

[39]

Scott LJ. 2018. Apatinib: a review in advanced gastric cancer and other advanced cancers. Drugs 78:747−58

doi: 10.1007/s40265-018-0903-9

[40]

Lin B, Song X, Yang D, Bai D, Yao Y, et al. 2018. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1. Gene 654:77−86

doi: 10.1016/j.gene.2018.02.026

[41]

Abbaspour Babaei M, Kamalidehghan B, Saleem M, Huri HZ, Ahmadipour F. 2016. Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells. Drug Design, Development and Therapy 10:2443−59

doi: 10.2147/DDDT.S89114

[42]

Levina V, Marrangoni A, Wang T, Parikh S, Su Y, et al. 2010. Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. Cancer Research 70:338−46

[43]

Mulligan LM. 2014. RET revisited: expanding the oncogenic portfolio. Nature Reviews 14:173−86

doi: 10.1038/nrc3680

[44]

Touat M, Ileana E, Postel-Vinay S, André F, Soria JC. 2015. Targeting FGFR signaling in cancer. Clinical Cancer Research 21:2684−94

doi: 10.1158/1078-0432.CCR-14-2329

[45]

Babina IS, Turner NC. 2017. Advances and challenges in targeting FGFR signalling in cancer. Nature Reviews Cancer 17:318−32

doi: 10.1038/nrc.2017.8

[46]

Szturz P, Raymond E, Abitbol C, Albert S, de Gramont A, et al. 2017. Understanding c-MET signalling in squamous cell carcinoma of the head & neck. Critical Reviews in Oncology/Hematology 111:39−51

doi: 10.1016/j.critrevonc.2017.01.004

[47]

Yang L, Zhou X, Sun J, Lei Q, Wang Q, et al. 2020. Reactive oxygen species mediate anlotinib-induced apoptosis via activation of endoplasmic reticulum stress in pancreatic cancer. Frontiers in Cell and Developmental Biology 11:766

doi: 10.1038/s41419-020-02938-4

[48]

Zhang X, Liu Y, Zhang Z, Tan J, Zhang J, et al. 2021. Multi-omics analysis of anlotinib in pancreatic cancer and development of an anlotinib-related prognostic signature. Frontiers in Cell and Developmental Biology 9:649265

doi: 10.3389/fcell.2021.649265

[49]

Su Y, Luo B, Lu Y, Wang D, Yan J, et al. 2022. Anlotinib induces a T cell-inflamed tumor microenvironment by facilitating vessel normalization and enhances the efficacy of PD-1 checkpoint blockade in neuroblastoma. Clinical Cancer Research 28:793−809

doi: 10.1158/1078-0432.CCR-21-2241

[50]

Qiu X, Lu C, Sha H, Zhu Y, Kong W, et al. 2024. Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, phase II clinical trial. Frontiers in Immunology 15:1210859

doi: 10.3389/fimmu.2024.1210859

[51]

Nan X, Xie C, Zhu Q, Zhang J, Fu S, et al. 2020. Hand-foot syndrome and survival in patients with advanced non-small-cell lung cancer receiving anlotinib: a subgroup analysis of data from the ALTER 0303 study. International Journal of Clinical Oncology 25:1492−98

doi: 10.1007/s10147-020-01683-0